## Laurent Devel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4532986/publications.pdf

Version: 2024-02-01

471509 454955 1,266 30 17 30 citations h-index g-index papers 31 31 31 1444 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Practical Synthesis of Phosphinic Dipeptides by Tandem Esterification of Aminophosphinic and Acrylic Acids under Silylating Conditions. Molecules, 2022, 27, 1242.	3.8	3
2	Monitoring In Vivo Performances of Protein–Drug Conjugates Using Site-Selective Dual Radiolabeling and Ex Vivo Digital Imaging. Journal of Medicinal Chemistry, 2022, 65, 6953-6968.	6.4	6
3	Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacological Reviews, 2022, 74, 714-770.	16.0	95
4	Ligandâ€Directed Modification of Active Matrix Metalloproteases: Activityâ€based Probes with no Photolabile Group. Angewandte Chemie, 2021, 133, 18420-18427.	2.0	0
5	Ligandâ€Directed Modification of Active Matrix Metalloproteases: Activityâ€based Probes with no Photolabile Group. Angewandte Chemie - International Edition, 2021, 60, 18272-18279.	13.8	8
6	Targeting out of range biomolecules: Chemical labeling strategies for qualitative and quantitative MALDI MS-based detection. TrAC - Trends in Analytical Chemistry, 2021, 143, 116399.	11.4	8
7	Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging. Journal of Medicinal Chemistry, 2020, 63, 15037-15049.	6.4	12
8	Analytical Methods for the Detection and Quantification of ADCs in Biological Matrices. Pharmaceuticals, 2020, 13, 462.	3.8	15
9	Novel Matrix Metalloproteinase 12 Selective Radiotracers for Vascular Molecular Imaging. Journal of Medicinal Chemistry, 2019, 62, 9743-9752.	6.4	13
10	Biodistribution of Nanostructured Lipid Carriers in Mice Atherosclerotic Model. Molecules, 2019, 24, 3499.	3.8	7
11	Synthesis and Structural/Functional Characterization of Selective M14 Metallocarboxypeptidase Inhibitors Based on Phosphinic Pseudopeptide Scaffold: Implications on the Design of Specific Optical Probes. Journal of Medicinal Chemistry, 2019, 62, 1917-1931.	6.4	8
12	Late-Stage Diversification of Phosphinic Dehydroalanine Pseudopeptides Based on a Giese-Type Radical C-Alkylation Strategy. Organic Letters, 2019, 21, 4397-4401.	<b>4.</b> 6	4
13	Zinc–Metalloproteinase Inhibitors: Evaluation of the Complex Role Played by the Zinc-Binding Group on Potency and Selectivity. Journal of Medicinal Chemistry, 2017, 60, 403-414.	6.4	27
14	Optical imaging of MMP-12 active form in inflammation and aneurysm. Scientific Reports, 2016, 6, 38345.	3.3	20
15	Synthesis and in Vitro and in Vivo Evaluation of MMP-12 Selective Optical Probes. Bioconjugate Chemistry, 2016, 27, 2407-2417.	3.6	26
16	Probing the Mechanism of Allylic Substitution of Morita–Baylis–Hillman Acetates (MBHAs) by using the Silyl Phosphonite Paradigm: Scope and Applications of a Versatile Transformation. Chemistry - A European Journal, 2015, 21, 3278-3289.	3.3	15
17	In Vivo Imaging of Matrix Metalloproteinase 12 and Matrix Metalloproteinase 13 Activities in the Mouse Model of Collagenâ€Induced Arthritis. Arthritis and Rheumatology, 2014, 66, 589-598.	5 <b>.</b> 6	29
18	A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nature Medicine, 2014, 20, 493-502.	30.7	218

#	Article	IF	CITATIONS
19	Crystallization of bi-functional ligand protein complexes. Journal of Structural Biology, 2013, 182, 246-254.	2.8	45
20	Molecular Determinants of a Selective Matrix Metalloprotease-12 Inhibitor: Insights from Crystallography and Thermodynamic Studies. Journal of Medicinal Chemistry, 2013, 56, 1149-1159.	6.4	37
21	Screening Using Polymorphs for the Crystallization of Protein–Ligand Complexes. Crystal Growth and Design, 2013, 13, 1878-1888.	3.0	14
22	Simple Pseudo-dipeptides with a P2′ Glutamate. Journal of Biological Chemistry, 2012, 287, 26647-26656.	3 <b>.</b> 4	35
23	A Selective Matrix Metalloproteinase-12 Inhibitor Retards Atherosclerotic Plaque Development in Apolipoprotein E–Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 528-535.	2.4	144
24	Insights from Selective Non-phosphinic Inhibitors of MMP-12 Tailored to Fit with an S1′ Loop Canonical Conformation. Journal of Biological Chemistry, 2010, 285, 35900-35909.	3 <b>.</b> 4	48
25	Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the $S1\hat{a}\in^2$ cavity. Biochimie, 2010, 92, 1501-1508.	2.6	88
26	Detection of Matrix Metalloproteinase Active Forms in Complex Proteomes: Evaluation of Affinity versus Photoaffinity Capture. Journal of Proteome Research, 2009, 8, 2484-2494.	3.7	22
27	Molecular Determinants of Matrix Metalloproteinase-12 Covalent Modification by a Photoaffinity Probe. Journal of Biological Chemistry, 2008, 283, 31058-31067.	3.4	27
28	Cross-Linking Yield Variation of a Potent Matrix Metalloproteinase Photoaffinity Probe and Consequences for Functional Proteomics. Angewandte Chemie - International Edition, 2007, 46, 3275-3277.	13.8	42
29	Development of Selective Inhibitors and Substrate of Matrix Metalloproteinase-12. Journal of Biological Chemistry, 2006, 281, 11152-11160.	3.4	134
30	Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie, 2005, 87, 393-402.	2.6	109